Areas of Uncertainty in SARS-CoV-2 Vaccination for Cancer Patients
Early in the COVID-19 pandemic, it was recognized that infection with SARS-CoV-2 is associated with increased morbidity and mortality in patients with cancer; therefore, preventive vaccination in cancer survivors is expected to be particularly impactful. Heterogeneity in how a neoplastic disease dia...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/12/2117 |
| _version_ | 1797455011975790592 |
|---|---|
| author | Anastasios Dimou |
| author_facet | Anastasios Dimou |
| author_sort | Anastasios Dimou |
| collection | DOAJ |
| description | Early in the COVID-19 pandemic, it was recognized that infection with SARS-CoV-2 is associated with increased morbidity and mortality in patients with cancer; therefore, preventive vaccination in cancer survivors is expected to be particularly impactful. Heterogeneity in how a neoplastic disease diagnosis and treatment interferes with humoral and cellular immunity, however, poses a number of challenges in vaccination strategies. Herein, the available literature on the effectiveness of COVID-19 vaccines among patients with cancer is critically appraised under the lens of anti-neoplastic treatment optimization. The objective of this review is to highlight areas of uncertainty, where more research could inform future SARS-CoV-2 immunization programs and maximize benefits in the high-risk cancer survivor population, and also minimize cancer treatment deviations from standard practices. |
| first_indexed | 2024-03-09T15:45:25Z |
| format | Article |
| id | doaj.art-1698265bc9634e96b6e39e044e40dc07 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T15:45:25Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-1698265bc9634e96b6e39e044e40dc072023-11-24T18:33:03ZengMDPI AGVaccines2076-393X2022-12-011012211710.3390/vaccines10122117Areas of Uncertainty in SARS-CoV-2 Vaccination for Cancer PatientsAnastasios Dimou0Division of Medical Oncology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USAEarly in the COVID-19 pandemic, it was recognized that infection with SARS-CoV-2 is associated with increased morbidity and mortality in patients with cancer; therefore, preventive vaccination in cancer survivors is expected to be particularly impactful. Heterogeneity in how a neoplastic disease diagnosis and treatment interferes with humoral and cellular immunity, however, poses a number of challenges in vaccination strategies. Herein, the available literature on the effectiveness of COVID-19 vaccines among patients with cancer is critically appraised under the lens of anti-neoplastic treatment optimization. The objective of this review is to highlight areas of uncertainty, where more research could inform future SARS-CoV-2 immunization programs and maximize benefits in the high-risk cancer survivor population, and also minimize cancer treatment deviations from standard practices.https://www.mdpi.com/2076-393X/10/12/2117T cell assaycellular immunityhumoral immunityneutralizing antibodies |
| spellingShingle | Anastasios Dimou Areas of Uncertainty in SARS-CoV-2 Vaccination for Cancer Patients Vaccines T cell assay cellular immunity humoral immunity neutralizing antibodies |
| title | Areas of Uncertainty in SARS-CoV-2 Vaccination for Cancer Patients |
| title_full | Areas of Uncertainty in SARS-CoV-2 Vaccination for Cancer Patients |
| title_fullStr | Areas of Uncertainty in SARS-CoV-2 Vaccination for Cancer Patients |
| title_full_unstemmed | Areas of Uncertainty in SARS-CoV-2 Vaccination for Cancer Patients |
| title_short | Areas of Uncertainty in SARS-CoV-2 Vaccination for Cancer Patients |
| title_sort | areas of uncertainty in sars cov 2 vaccination for cancer patients |
| topic | T cell assay cellular immunity humoral immunity neutralizing antibodies |
| url | https://www.mdpi.com/2076-393X/10/12/2117 |
| work_keys_str_mv | AT anastasiosdimou areasofuncertaintyinsarscov2vaccinationforcancerpatients |